Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma

Zhang, Ya; Wang, Jianhong; Sui, Xiaohui; Liu, Ying; Lu, Kang; Fang, Xiaosheng; Jiang, Yujie; Wang, Xin

doi:10.1097/md.0000000000001432

Cited by 18 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our result goes in agreement with Mahsa et al, [8] who revealed a correlation between survivin gene expression and a clinically unfavorable course of paediatric precursor B-cell ALL (BCP-ALL), suggesting that survivin expression is a poor prognostic factor. That also agreed with Zhang Y et al, [6] who found that survivin is overexpressed in relapsed pediatric ALL patients.…”

Section: Discussionsupporting

confidence: 80%

“…Survivin, a small inhibitor-of-apoptosis protein (IAP) encoded by the baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) gene plays a critical role in apoptosis, cell division, and proliferation [5]. Survivin gene newly named BIRC5 can be regarded as an oncogene as its overexpression in cancer cells contributes to their resistance to apoptosis and therapies, thus contributing to their ongoing survival [6]. It prevents apoptosis by blocking caspases activity [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of BIRC5 Gene as a Prognostic Marker in Pediatric Acute Lymphoblastic Leukemia

Al-Sharkawy¹,

Ag²,

Amk³

et al. 2017

J Blood Lymph

View full text Add to dashboard Cite

Patients were followed up for two years and the outcome was designated either favorable or unfavorable. Favorable outcome was AbstractBackground and objectives: Acute lymphoblastic leukaemia (ALL) is the most common malignancy diagnosed in children. Survivin, a small inhibitor-of-apoptosis protein (IAP) encoded by the baculoviral inhibitor of apoptosis repeat-Containing 5 (BIRC5) gene, plays critical roles in malignancy by preventing apoptosis through blocking caspase activity. The aim of this study was to assess the prognostic role of BIRC5 gene in paediatric ALL. Subjects and methods:The present study was carried out on 42 children with the' novo ALL who were followed up for two years and 10 apparently healthy children of matched age and sex (controls). Each child was subjected to complete history taking, clinical examination, laboratory investigations the form of CBC, Leishman-stained peripheral blood smears, Lactate dehydrogenase (LDH), Bone marrow (BM) aspiration and examination of Leishman-stained smears, Immunophenotyping on BM samples for routine panel of ALL determined by flow cytometer and quantitative determination of survivin gene expression by real time PCR on BM samples.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Role of BIRC5 Gene as a Prognostic Marker in Pediatric Acute Lymphoblastic Leukemia

Al-Sharkawy¹,

Ag²,

Amk³

et al. 2017

J Blood Lymph

View full text Add to dashboard Cite

show abstract

“…Previous lymphoma studies have shown that survivin overexpression is associated with poor survival outcomes [17, 19]. However, there are some pitfalls in the interpretation of previous data.…”

Section: Discussionmentioning

confidence: 99%

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

et al. 2017

View full text Add to dashboard Cite

Survivin is an inhibitor of apoptosis and is upregulated by Epstein–Barr virus (EBV) latent genes. Given the frequent association of EBV with lymphoid malignancies, survivin is expected to have prognostic value in diffuse large B-cell lymphoma (DLBCL). Thus, we measured the pretreatment serum level of survivin in DLBCL patients and analyzed its association with survival outcome and EBV status, as represented by EBV-encoded RNA (EBER) in DLBCL. Pretreatment serum survivin level was measured in patients registered in a prospective cohort study (n = 210), and serum survivin-positivity was defined as any detectable level of survivin. EBV status was determined using EBER in situ hybridization, and EBER-positivity was defined as 20% of examined cells showing nuclear positivity. Mean serum survivin level was higher in patients with relapsed or refractory disease than with responsive disease (59.89 pg/mL versus 17.34 pg/mL, P = 0.041). Serum survivin-positive patients had worse overall and progression-free survival (P = 0.023 and 0.022, respectively). Serum survivin positivity was associated with unfavorable characteristics including stage. In patients with non-germinal center B-cell type DLBCL, serum survivin-positive patients also had significantly worse survival than serum survivin-negative patients (P < 0.001). EBER-positivity was found in 6.7% (14/210) of patients, and EBER-positive patients had worse survival (P < 0.05). Patients having concomitant positivity for serum survivin and EBER expression (2.8%, 6/210) showed extremely poor prognosis. In the present era of rituximab in DLBCL, DLBCL with serum survivin positivity showed adverse clinical features and followed worse clinical course, especially in non-GCB subtype DLBCL. EBER-positivity was still associated with worse outcomes in DLBCL.

show abstract

“…However, more than 30% of DLBCL will ultimately relapse [4]. The International Prognostic Index (IPI) was commonly used to predict response and prognosis in patients with aggressive lymphomas [5,6]. Thereafter, clinical risk stratification models such as the revised IPI (R-IPI) [7], the biological markeradjusted IPI (B-IPI) [8], the National Comprehensive Cancer Network IPI (NCCN-IPI) [9] were proposed to modify the declined capacity of IPI.…”

Section: Introductionmentioning

confidence: 99%

Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP

Wang

Zhou

Wang

et al. 2016

Clinica Chimica Acta

View full text Add to dashboard Cite

Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma

Abstract: Supplemental Digital Content is available in the text

Cited by 18 publications

References 29 publications

Role of BIRC5 Gene as a Prognostic Marker in Pediatric Acute Lymphoblastic Leukemia

Role of BIRC5 Gene as a Prognostic Marker in Pediatric Acute Lymphoblastic Leukemia

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP

Contact Info

Product

Resources

About